Skip to content

Jazz Pharmaceuticals JAZZ Derivative Liabilities, Gross

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$14.11B+54.4%
Enterprise value$18.85B+47.7%
P/S3.2×+0.9×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement.

The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Jazz Pharmaceuticals's derivative liabilities, gross.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Jazz Pharmaceuticals's derivative liabilities, gross?
Jazz Pharmaceuticals (JAZZ) reported derivative liabilities, gross of $8.5M in Q1 2026.
How has Jazz Pharmaceuticals's derivative liabilities, gross changed year-over-year?
Jazz Pharmaceuticals's derivative liabilities, gross increased by 5114.7% year-over-year, from $163K to $8.5M.
What is the long-term trend for Jazz Pharmaceuticals's derivative liabilities, gross?
Over 4 years (2020 to 2025), Jazz Pharmaceuticals's derivative liabilities, gross has grown at a 3.7% compound annual growth rate (CAGR), from $3.63M to $4.2M.